NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug [Yahoo! Finance]
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results [Yahoo! Finance]
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal [Yahoo! Finance]